These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 25305449)

  • 1. Dynamic bioluminescence and fluorescence imaging of the effects of the antivascular agent Combretastatin-A4P (CA4P) on brain tumor xenografts.
    Liu L; Mason RP; Gimi B
    Cancer Lett; 2015 Jan; 356(2 Pt B):462-9. PubMed ID: 25305449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antivascular effects of combretastatin A4 phosphate in breast cancer xenograft assessed using dynamic bioluminescence imaging and confirmed by MRI.
    Zhao D; Richer E; Antich PP; Mason RP
    FASEB J; 2008 Jul; 22(7):2445-51. PubMed ID: 18263704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intra-individual comparison of therapeutic responses to vascular disrupting agent CA4P between rodent primary and secondary liver cancers.
    Liu YW; De Keyzer F; Feng YB; Chen F; Song SL; Swinnen J; Bormans G; Oyen R; Huang G; Ni YC
    World J Gastroenterol; 2018 Jul; 24(25):2710-2721. PubMed ID: 29991876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The development of combretastatin A4 phosphate as a vascular targeting agent.
    Chaplin DJ; Hill SA
    Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1491-6. PubMed ID: 12459376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tubulin-destabilizing agent BPR0L075 induces vascular-disruption in human breast cancer mammary fat pad xenografts.
    Liu L; Beck H; Wang X; Hsieh HP; Mason RP; Liu X
    PLoS One; 2012; 7(8):e43314. PubMed ID: 22937031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.
    Stevenson JP; Rosen M; Sun W; Gallagher M; Haller DG; Vaughn D; Giantonio B; Zimmer R; Petros WP; Stratford M; Chaplin D; Young SL; Schnall M; O'Dwyer PJ
    J Clin Oncol; 2003 Dec; 21(23):4428-38. PubMed ID: 14645433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors.
    Dziba JM; Marcinek R; Venkataraman G; Robinson JA; Ain KB
    Thyroid; 2002 Dec; 12(12):1063-70. PubMed ID: 12593719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity.
    Salmon HW; Siemann DW
    Clin Cancer Res; 2006 Jul; 12(13):4090-4. PubMed ID: 16818709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model.
    Malcontenti-Wilson C; Muralidharan V; Skinner S; Christophi C; Sherris D; O'Brien PE
    Clin Cancer Res; 2001 Apr; 7(4):1052-60. PubMed ID: 11309357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combretastatin A4 phosphate: a novel vascular disrupting agent.
    Nagaiah G; Remick SC
    Future Oncol; 2010 Aug; 6(8):1219-28. PubMed ID: 20799867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combretastatin A4 phosphate.
    West CM; Price P
    Anticancer Drugs; 2004 Mar; 15(3):179-87. PubMed ID: 15014350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The first study on therapeutic efficacies of a vascular disrupting agent CA4P among primary hepatocellular carcinomas with a full spectrum of differentiation and vascularity: Correlation of MRI-microangiography-histopathology in rats.
    Liu Y; De Keyzer F; Wang Y; Wang F; Feng Y; Chen F; Yu J; Liu J; Song S; Swinnen J; Bormans G; Oyen R; Huang G; Ni Y
    Int J Cancer; 2018 Oct; 143(7):1817-1828. PubMed ID: 29707770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early effects of combretastatin A4 phosphate assessed by anatomic and carbogen-based functional magnetic resonance imaging on rat bladder tumors implanted in nude mice.
    Thomas CD; Walczak C; Kaffy J; Pontikis R; Jouanneau J; Volk A
    Neoplasia; 2006 Jul; 8(7):587-95. PubMed ID: 16867221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate.
    Hua J; Sheng Y; Pinney KG; Garner CM; Kane RR; Prezioso JA; Pettit GR; Chaplin DJ; Edvardsen K
    Anticancer Res; 2003; 23(2B):1433-40. PubMed ID: 12820406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combretastatin A4 phosphate: background and current clinical status.
    Young SL; Chaplin DJ
    Expert Opin Investig Drugs; 2004 Sep; 13(9):1171-82. PubMed ID: 15330748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P).
    Siemann DW; Chaplin DJ; Walicke PA
    Expert Opin Investig Drugs; 2009 Feb; 18(2):189-97. PubMed ID: 19236265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single dose of intravenous combretastatin A4-phosphate is reasonably well tolerated and significantly reduces tumour vascularization in canine spontaneous cancers.
    Abma E; De Spiegelaere W; Vanderperren K; Stock E; Van Brantegem L; Cornelis I; Daminet S; Ni Y; Vynck M; Verstraete G; Smets P; de Rooster H
    Vet Comp Oncol; 2018 Dec; 16(4):467-477. PubMed ID: 29797763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancer.
    Ng QS; Goh V; Carnell D; Meer K; Padhani AR; Saunders MI; Hoskin PJ
    Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1375-80. PubMed ID: 17275203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate.
    Lunt SJ; Akerman S; Hill SA; Fisher M; Wright VJ; Reyes-Aldasoro CC; Tozer GM; Kanthou C
    Int J Cancer; 2011 Oct; 129(8):1979-89. PubMed ID: 21154772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A poly(l-glutamic acid)-combretastatin A4 conjugate for solid tumor therapy: Markedly improved therapeutic efficiency through its low tissue penetration in solid tumor.
    Liu T; Zhang D; Song W; Tang Z; Zhu J; Ma Z; Wang X; Chen X; Tong T
    Acta Biomater; 2017 Apr; 53():179-189. PubMed ID: 28167300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.